Dr. Ryan Alan Shields, MD

Dr. Shields practices at Retina Group Of Florida in Fort Lauderdale, Florida.

Dr. Shields' NPI, 1255726618, was assigned on April 2, 2015. Dr. Shields graduated from Northeast Ohio Medical University in 2015. Dr. Shields holds Florida license ME148306.

Dr. Shields' primary practice is Retina Group of Florida, at 6333 N Federal Hwy Ste 300 Suite 300, Fort Lauderdale, FL 33308. The practice phone is (954) 776-6880.

Dr. Shields' primary practice is Retina Group Of Florida in Fort Lauderdale, Florida. Dmand AI also links Dr. Shields to 1 medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shields practices. Vendor and product names are available with a free account.

Retina specialist is Dr. Shields' primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Shields is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Shields' licenses on file in 3 states: Florida, Michigan and California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy and inflammation of iris among the conditions Dr. Shields treats.

CMS data shows 36,623 Medicare services from Dr. Shields across 22 procedure codes in 2024, for 990 Medicare patients. Medicare paid $2,726,340 for them.

CMS counts 990 Medicare patients who saw Dr. Shields in 2024. The largest group is 75 to 84, with 395 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shields' median patient age at 73, with 51% women.

In 2024, Dr. Shields wrote 550 Medicare Part D claims for 244 patients. 63% of them were for generic drugs. CMS names the drug for 484 of them, across 12 drugs with 11 or more claims each, at $26,248 in total drug cost. In 2023, CMS named 563 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Shields for performance year 2024, reported as part of a group. Dr. Shields accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 19 procedures of cataract surgery by Dr. Shields, more than 43% of the clinicians it reports for that procedure.

Dmand AI links 24 papers to Dr. Shields, published from 2018 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Vitrectomy, Visual Acuity and Vitreous Body. Dr. Shields has published most often in Ophthalmic Surg Lasers Imaging Retina. Dr. Shields' most frequent co-authors are Tarek Shawky Hassan, MD, Darius Mohammad Moshfeghi, MD and Jeremy D. Wolfe, MD.

CMS Open Payments shows 141 general payments to Dr. Shields from 30 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 71% of the total. Genentech, Inc. paid the most, $3,289.

Dmand AI lists 1 award for Dr. Shields.

Dr. Shields graduated from Northeast Ohio Medical University in 2015.

Dr. Shields is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.